Combination benefit with regard to cell growth/ proliferation inhibition was achieved with LXH254 plus trametinib in NF1-null MPNST cell lines using three complementary assays, IncuCyte real-time monitoring of cell confluence (Figs. 4A, S4A-B), cell viability assay (Figs. 4B and S4C) and 2-dimensional colony formation assay (Figs. 4C and S4D). This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.